ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
9.11
+0.16 (1.79%)
At close: Sep 18, 2026, 4:00 PM EDT
9.09
-0.02 (-0.22%)
After-hours: Sep 18, 2026, 7:32 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, ADMA Biologics stock has a consensus rating of "Buy" and an average price target of $17. The average 1-year stock price forecast is 86.61% higher than the current stock price, while the lowest is $12 (+31.72%) and the highest is $21 (+130.52%).
Price Target: $17 (+86.61%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Aug 6, 2026.
Analyst Ratings
The average analyst rating for ADMA Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $12 | Hold | Maintains | $12 | +31.72% | Aug 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $18 | Buy | Maintains | $18 | +97.59% | Aug 6, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +86.61% | Jul 15, 2026 |
| Raymond James | Raymond James | Buy Initiates $21 | Buy | Initiates | $21 | +130.52% | Jun 10, 2026 |
Financial Forecast
Revenue This Year
535.35M
from 510.17M
Increased by 4.93%
Revenue Next Year
666.03M
from 535.35M
Increased by 24.41%
EPS This Year
0.80
from 0.66
Increased by 21.31%
EPS Next Year
0.94
from 0.80
Increased by 18.41%
EPS and Forward PE are based on non-GAAP adjusted numbers.